Artificial Intelligence-Based Diets: A Role in the Nutritional Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease?

被引:0
|
作者
Karahan, Tugce Ozlu [1 ]
Kenger, Emre Batuhan [1 ]
Yilmaz, Yusuf [2 ]
机构
[1] Istanbul Bilgi Univ, Fac Hlth Sci, Dept Nutr & Dietet, Istanbul, Turkiye
[2] Recep Tayyip Erdogan Univ, Sch Med, Dept Gastroenterol, Rize, Turkiye
关键词
artificial intelligence; ChatGPT; guideline recommendations; metabolic dysfunction-associated steatotic liver disease; nutritional therapy; PRACTICE GUIDANCE; MANAGEMENT; ENERGY;
D O I
10.1111/jhn.70033
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern. Effective management of this condition relies heavily on lifestyle modifications and dietary interventions. In this study, we sought to evaluate the dietary plans for MASLD generated by ChatGPT (GPT-4o) according to current guideline recommendations. Methods: ChatGPT was used to create single-day meal plans for 48 simulated patients with MASLD, tailored to individual characteristics such as age, gender, height, weight and transient elastography parameters. The plans were assessed for appropriateness according to disease-specific guidelines. Results: The mean energy content of the menus planned by ChatGPT was 1596.9 +/- 141.5 kcal with a mean accuracy of 91.3 +/- 11.0%, and fibre content was 22.0 +/- 0.6 g with a mean accuracy of 88.1 +/- 2.5%. However, they exhibited elevated levels of protein, fat and saturated fat acids. Conversely, the carbohydrate content was lower. ChatGPT recommended weight loss for obese patients but did not extend this advice to normal-weight and overweight individuals. Notably, recommendations for a Mediterranean diet and physical activity were absent. Conclusions: ChatGPT shows potential in developing dietary plans for MASLD management. However, discrepancies in macronutrient distributions and the omission of key evidence-based recommendations highlight the need for further refinement. To enhance the effectiveness of AI tools in dietary recommendations, alignment with established guidelines must be improved.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The Role of RNA Splicing in Liver Function and Disease: A Focus on Metabolic Dysfunction-Associated Steatotic Liver Disease
    Kaminska, Dorota
    GENES, 2024, 15 (09)
  • [42] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [43] Role of Spleen Stiffness Measurement in the Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Williams, Elizabeth E.
    Mladenovic, Andrea
    Ranginani, Dheeksha
    Weber, Regina
    Samala, Niharika
    Gawrieh, Samer
    Vilar-Gomez, Eduardo
    Chalasani, Naga
    Vuppalanchi, Raj
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (04) : 1444 - 1453
  • [44] Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism
    Feng, Xiaoxi
    Zhang, Rutong
    Yang, Zhenye
    Zhang, Kaiguang
    Xing, Jun
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (09) : 815 - 826
  • [45] Role of Spleen Stiffness Measurement in the Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Elizabeth E. Williams
    Andrea Mladenovic
    Dheeksha Ranginani
    Regina Weber
    Niharika Samala
    Samer Gawrieh
    Eduardo Vilar-Gomez
    Naga Chalasani
    Raj Vuppalanchi
    Digestive Diseases and Sciences, 2024, 69 : 1444 - 1453
  • [46] Systematic review of exercise for the treatment of pediatric metabolic dysfunction-associated steatotic liver disease
    Smith, Martha R.
    Yu, Elizabeth L.
    Malki, Ghattas J.
    Newton, Kimberly P.
    Goyal, Nidhi P.
    Heskett, Karen M.
    Schwimmer, Jeffrey B.
    PLOS ONE, 2024, 19 (12):
  • [47] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    LIFE-BASEL, 2024, 14 (07):
  • [48] SYSTEMATIC REVIEW OF EXERCISE FOR THE TREATMENT OF PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
    Smith, Martha
    Yu, Elizabeth
    Malki, Ghattas
    Newton, Kimberly
    Goyal, Nidhi
    Heskett, Karen
    Schwimmer, Jeffrey
    HEPATOLOGY, 2024, 80 : S1949 - S1950
  • [49] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [50] METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IS ASSOCIATED WITH LIVER FIBROSIS IN HEPATITIS C
    Elgretli, Wesal
    Shengir, Mohamed
    Sasson, Solomon
    Agnihotram, V. Ramanakumar
    Ballesteros, Luz Esther Ramos
    Deschenes, Marc
    Wong, Philip
    Chen, Tianyan
    Kronfli, Nadine
    Keeshan, Alexa
    Tandon, Saniya
    Cooper, Curtis
    Sebastiani, Giada
    HEPATOLOGY, 2024, 80 : S382 - S383